Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.
Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. The website, which houses data from several clinical trial sponsors, was created with support from PhRMA and EFPIA to increase access to and transparency of clinical trial results for researchers around the world.
The new portal, www.clinicalstudydatarequest.com, differs from previous Lilly data-sharing sites in that access will only be granted after approval of a research proposal by an independent scientific review panel. Lilly will not be involved in the decisions made by the independent scientific review panel.
The multi-sponsor portal will include Lilly-sponsored interventional clinical studies from approved medicines and indications in the U.S. and EU in the following categories:
Lilly established www.lillyclinicalstudydata.com in January 2014 in an interim capacity. This will be replaced by the new site.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.